Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops… Read full dossier
CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL
INITIALIZE TERMINAL
Select up to 5 assets to monitor in your personal Watchlist. This builds your core market profile.
GUEST MODE: Watchlist is temporary. Login or Register to sync permanently and unlock Top 1-5 Champions.
UNITED STATES
